key: cord-0890811-whscathm
authors: Paternoster, Gianluca; Bertini, Pietro; Innelli, Pasquale; Trambaiolo, Paolo; Landoni, Giovanni; Franchi, Federico; Scolletta, Sabino; Guarracino, Fabio
title: Right Ventricular Dysfunction in Patients With COVID-19: a systematic review and meta-analysis
date: 2021-04-11
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2021.04.008
sha: 0986b4138a7609131d221e85b1c8ffdbb2bf4a9b
doc_id: 890811
cord_uid: whscathm

OBJECTIVE: This systematic review and meta-analysis aimed to describe the features of right ventricular impairment and pulmonary hypertension in COVID-19 and assess its effect on mortality. DESIGN: We carried out a systematic review and meta-analysis of observational studies. SETTING: We performed a search through Pubmed, the International Clinical Trials Registry Platform, and the Cochrane Library for studies reporting right ventricular dysfunction in COVID-19 patients and outcomes. PARTICIPANTS: The search yielded 9 studies in which the appropriate data were available. INTERVENTIONS: Pooled odds ratio were calculated according to the random effects model. MEASUREMENTS AND MAIN RESULTS: Overall, 1450 patients were analyzed, half of them invasively ventilated. Primary outcome was mortality at the longest follow-up available. Mortality was 48.5% versus 24.7% in patients with or without right ventricular impairment, (n = 7, OR = 3.10; 95% CI 1.72 – 5.58; p = 0.0002), 56.3% versus 30.6%, in patients with or without right ventricular dilatation (n = 6; OR = 2.43; 95% CI 1.41 – 4.18; p = 0.001), and 52.9% versus 14.8% in patients with or without pulmonary hypertension, (n = 3; OR = 5.75; 95% confidence intervals 2.67 – 12.38; p < 0.001). CONCLUSION: Mortality of COVID-19 patients requiring respiratory support and with a diagnosis of right ventricular dysfunction, dilatation or pulmonary hypertension, is high. Future studies should highlight the mechanisms of right ventricular derangement in COVID-19 while early detection of right ventricular impairment using ultrasound might be important to individualize therapies and improve outcomes.

In December 2019, an outbreak of pneumonia emerged in Wuhan (Hubei Province, China), and was quickly discovered to be caused by a new coronavirus lately called Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) causing the coronavirus disease . Since then, the disease has spread rapidly to other provinces of mainland China and more than 200 countries so far, being recognized as a pandemic by the World Health Organization (WHO) in March 2020 1 2 .

The main clinical feature of the infection is respiratory involvement, furtherly expressing to respiratory insufficiency needing supportive therapy with high flow oxygen or non-invasive mechanical ventilation and eventually acute respiratory distress syndrome (ARDS) requiring invasive ventilation, prone positioning and, in severe cases, veno-venous extracorporeal oxygenation (VV-ECMO) 3 .

Respiratory failure in COVID-19 patients presents as a combination of two processes: viral pneumonia and ARDS. These conditions can cause diffuse alveolar damage with hyaline membrane formation followed by interstitial widening, edema, and fibrosis due to inflammation and proliferative disease 4 .

Another finding in COVID-19 related ARDS could be pulmonary thrombosis that might involve pulmonary micro-vessels suggesting thrombotic microangiopathy and causing pulmonary hypertension (PH) that is likely to increase mortality 5 6 . This disorder could explain unexpected manifestation as dilated pulmonary vessels and right ventricular dysfunction 7 . In patients with COVID-19 related ARDS, pulmonary hypertension might be also due to the involvement of ACE 2 receptors and the effects of chemokines and cytokines 8 . Notably, cardiac failure, in particular RV dysfunction, is commonly encountered in moderate to severe non-COVID-19 ARDS and is reported to be one of the major determinants of mortality 9 .

The aim of this systematic review and meta-analysis was to determine if echocardiographic evidence of RV dysfunction, echocardiographic evidence of RV dilation, or pulmonary hypertension are associated with mortality in COVID-19 patients.

We adhered to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) 10 to conduct and report this systematic review. The protocol was registered to the PROSPERO database with ID CRD42020216221.

We performed a thorough literature search in Pubmed, Cochrane Library, and the International Clinical Trials Registry Platform databases through Oct 23 2020 to identify published or ongoing studies on the subject. The keywords used were ("COVID-19" OR "SARS-CoV-2" OR "Coronavirus") AND ("right ventricle" OR "right heart" OR "echocardiography" OR "pulmonary hypertension" OR "pulmonary pressure"). We manually recorded the reference list of all significant publications.

Inclusion criteria were: all types of studies; investigating the right ventricular function or pulmonary pressure assessment using echocardiography; in adult patients with COVID-19; and reporting mortality data. We excluded studies involving patients < 18 years old, case reports or case series and narrative or systematic reviews. Titles and abstracts were subsequently screened by two reviewers (GP and PB) to recognize possibly relevant articles. The discrepancy in judgment was resolved after discussion. The retrieved full manuscripts were reviewed for relevancy and presence of outcomes of interest to generate the list of studies to be included in our quantitative analysis.

The risk of bias was assessed by the Cochrane risk-of-bias tool for randomized controlled trials. The methodological power of observational studies was evaluated by the Newcastle-Ottawa Scale (NOS) 11 . The NOS was designed to judge a study by three perspectives: the study's selection, the comparability, and the determination of the outcomes. Favorable judgment is made by awarding a star. Nine stars indicate the highest strength, and six or more stars design elevated quality.

A meta-analysis was performed when outcomes were reported in at least two studies. Odds ratio (OR) and 95% confidence intervals (CI) were estimated. Metric I 2 was used to assess heterogeneity among studies independently of the number of studies 12 . The random-effects model was used to calculate OR. Two-tailed p values with p<0.05 were judged as statistically significant. Publication bias was assessed by the funnel plot's visual inspection when more than ten studies were found.

The asymmetry of the funnel plot where detected by Egger's regression test 13 Right ventricular (RV) dysfunction was a assessed by at least one or a combination of the following: fractional area change (FAC) < 35%, tissue doppler-derived imaging (TDI) tricuspid lateral annular systolic velocity wave (S') < 9.5 cm/s, tricuspid annular plane systolic excursion (TAPSE) < 17mm, and RV index of myocardial performance (RIMP) by TDI > 0.43 as recommended by guidelines 14 . A diameter >41 mm at the base and >35 mm at the midlevel in the RV-focused view was used to identify RV dilatation 14 . PH was diagnosed by mean pulmonary arterial pressure (PAPm) >25mmHg as recommended in the guidelines 15 .

A list of 312 studies was identified through a literature search, among which 60 were duplicates, and 200 were excluded after an initial review of titles and abstracts. The remaining 28 publications full-text were reviewed and screened for inclusion criteria (Supplement Table 1 ). Finally, 9 were selected for the systematic review and meta-analysis 16, 17, 18, 19, 20, 21, 22, 23, 24 . The search and selection process were depicted in a PRISMA flow diagram (Figure 1 ).

Approximately half of the patients were invasively ventilated. Studies details and patients' characteristics are reported in Table 1 and Table 2 

The 9 included studies were of high quality according to the NOS assessment tool for cohort studies and the risk of bias evaluation is detailed in Supplemental Table 2 .

To our knowledge, this is the first systematic review and meta-analysis assessing the effects of RV dysfunction or dilatation in adult patients with COVID-19. We found a significantly increased mortality in patients with RV dysfunction and in those with RV dilatation and/or PH compared to other patients with COVID-19 without right ventricular acute alterations.

RV dysfunction in patients with ARDS is apparently a well known finding, however we have decided to perform the present meta-analysis after increasing evidence of a strong relationship between RV failure and mortality in COVID-19 patients as suggested by several authors 25 , 26 , 27 , 28 .

In the present meta-analysis, we included 9 observational studies that met our inclusion criteria to evaluate the impact of right ventricular alteration on outcome in COVID-19 patients. A recent survey on cardiac involvement in COVID-19 showed that the left ventricle was affected in 32% of the patients, RV in 42%, and both sides were involved in 21% of cases; interestingly, only in 5% of the patients, no cardiac involvement was reported 29 . Heart failure, particularly RV dysfunction, is commonly encountered in moderate to severe ARDS and is reported to be one significant determinant of mortality 30 .

The negative influence of high-pressure mechanical ventilation on hemodynamics has been recognized 31 as the inevitable rise in intrathoracic pressure caused by positive pressure ventilation, or PEEP is associated with a decrease in CO, probably mediated by impairment of venous return 32 .

RV dilatation, in response to afterload increase, raises the right ventricular distending pressure, which can reduce the pressure gradient for subendocardial coronary blood flow with corresponding right ventricular contractility reduction 33 .

Along with alveolar damage, ARDS directly causes injury to the pulmonary circulation through several pathophysiological mechanisms: hypoxic pulmonary vasoconstriction, the release of vasoconstrictive mediators, extrinsic vascular compression by interstitial edema, and blood vessel remodeling. All of these factors contribute to pulmonary vascular resistance (PVR) elevation, PH, right-ventricular afterload increase, and eventually, RV failure. RV dysfunction is a common and often primary cause of cardiovascular insufficiency in the critically ill 34 .

The pulmonary vascular bed is more sensitive to the vasoconstrictive influence of respiratory acidosis. Moreover, pulmonary vascular dysfunction might be associated with ARDS, leading to increased right ventricular afterload and eventually RV dysfunction.

In COVID-19 patients, a cytokine storm is common. Interleukin 6 (IL-6) serum concentration correlates with respiratory dysfunction, ARDS, and poor clinical outcomes. Also, SARS-CoV-2 direct injury to the RV is expected to increase the release of vasoactive peptides and promote myocardial recruitment of inflammatory cells. Cardiac myofibroblasts and cardiomyocytes act as a key source of a wide array of pro-inflammatory cytokines including IL-6 and are highly responsive to IL-6, IL-1β, and TNFα. Furthermore, prolonged/excessive synthesis of IL-6 is reported to induce cardiac hypertrophy, fibrosis, and diastolic dysfunction. The pro-inflammatory cytokines cascade can contribute to RV dysfunction through their negative inotropic effects on the myocardium. Taken together, the depressed RV contractility may prove to be fatal in the face of acutely elevated PVR from ARDS and pulmonary embolism in COVID-19 35 .

As demonstrated by our meta-analysis, the impact of the right ventricle involvement in COVID-19 on mortality highlights the importance of an echocardiographic screening in such patients throughout the clinical course, even if protective or non-invasive ventilation approaches are used 36 .

All the studies included in the metanalysis are observational. Also, clinical setting and ventilation protocols used varied in different studies and this should be considered. Moreover, echocardiographic RV assessment might not be homogeneous across the studies included in our meta-analysis.

Alteration in function or dimensions of the RV or PH in COVID-19 patients undergoing respiratory support, seems to play a major role in determining mortality rate. Thrombotic events, hypoxemic vasoconstriction, cytokine release, and direct viral damage are all possible contributors to RV derangement. Our analysis reinforces the need for a broader implementation of screening COVID-19 patients for right heart alteration and a focused ultrasound assessment might be important in patients presenting with COVID-19 needing respiratory support. 

An interactive web-based dashboard to track COVID-19 in real time

Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction

Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

Autopsy findings in COVID-19-related deaths: a literature review

Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis

Pulmonary Vascular Thrombosis in COVID-19 Pneumonia

Echocardiographic assessment of the right ventricle in COVID -related acute respiratory syndrome

Mechanisms of Pulmonary Hypertension in Acute Respiratory Distress Syndrome (ARDS)

The Right Ventricle in ARDS

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Measuring inconsistency in meta-analyses

Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy

Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension

Prognostic Value of Right Ventricular Longitudinal Strain in Patients With COVID-19

Prognostic Utility of Right Ventricular Remodeling Over Conventional Risk Stratification in Patients With COVID-19

Echocardiographic Findings in Patients With COVID-19 Pneumonia

Impact of Right Ventricular Dysfunction on Mortality in Patients Hospitalized with COVID-19 according to Race

Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection

Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19

Right Ventricular Dilation in Hospitalized Patients with COVID-19 Infection

Indications for and Findings on Transthoracic Echocardiography in COVID-19

Critical care ultrasonography during COVID-19 pandemic: The ORACLE protocol

Characterization of Myocardial Injury in Patients With COVID-19

Right ventricular-arterial uncoupling independently predicts survival in COVID-19 ARDS

Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study

Right Ventricular Function and Pulmonary Pressures as Independent Predictors of Survival in Patients With COVID-19 Pneumonia

Cardiovascular Consequences and Considerations of Coronavirus Infection -Perspectives for the Cardiothoracic Anesthesiologist and Intensivist During the Coronavirus Crisis

Rationale and Description of Right Ventricle-Protective Ventilation in ARDS

Acute respiratory distress syndrome: the heart side of the moon

Echocardiographic analysis of cardiac function during high PEEP ventilation

Right Ventricular Perfusion: Physiology and Clinical Implications

Novel applications of bedside monitoring to plumb patient hemodynamic state and response to therapy

the eye of the storm: the right ventricle in COVID-19

Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work

61(50.8-70.3) 72.2% NA NA 55

61±14 47.5% 21%

NA: not available; ICU: Intensive Care Unit; NIV: Non-invasive ventilation; MV: Mechanical ventilation